Abstract: Objective To compare the adverse drug reactions/adverse events (ADRs/AEs) caused by ticagrelor and clopidogrel, in order to provide reference for clinical safe and rational use of the antiplatelet agents. Methods ADR/AE cases caused by ticagrelor and clopidogrel were screened and analyzed statistically from ADR/AE cases reported in Shenzhen city from 2014 to 2017. Results 31 ADR/AE cases caused by ticagrelor and 43 caused by clopidogrel were screened out. All of the ADR/AE cases were mainly male, however, the ratio of ticagrelor males and females was more obvious. The onset time of most ADRs/AEs by ticagrelor was within 2 to 7 days after oral medication (35.48%), and that of clopidogrel was mostly within 1 day and 2 to 7 days (32.56%, 30.23%). The main clinical manifestations by ticagrelor were bleeding(56.46%) and dyspnea(33.33%). The involved system-organs and clinical manifestations by clopidogrel were more than that by ticagrelor. Most clinical manifestations by ticagrelor and clopidogrel were mild and had good prognosis, but the patients were more tolerant to ticagrelor compared with clopidogrel. One fatal case was reported by clopidogrel. Conclusion Clinicians and clinical pharmacists should pay more attention to monitor ADRs/AEs by tigrelor and copidogrel within one week. The bleeding and dyspnea by tigrelor should be more concerned. Clinic should strengthen medication monitoring to reduce ADRs and ensure drug safety.

Key words: ticagrelor, clopidogrel, adverse drug reactions/adverse events